Tags : axitinib

Merck Receives EU’s CHMP Positive Opinion for its Zerbaxa (ceftolozane

Shots: The positive CHMP opinion of Zerbaxa (3gm) is based on P-III ASPECT-NP study assessing Zerbaxa in patients with hospital-acquired pneumonia including ventilator-associated pneumonia. The EC will review CHMP’s opinion to grant centralized marketing authorization to the combination therapy The CHMP positive opinion of Keytruda + Inlyta is based on P-III KEYNOTE 426 study which […]Read More

Pfizer Reports Results of Bavencio (avelumab) + Inlyta (axitinib) in

Shots: The P-III JAVELIN Renal 101 trial involves assessing of Bavencio (avelumab) + Inlyta (axitinib) vs Sutent (sunitinib) in 886 patients with previously untreated advanced RCC P-III JAVELIN Renal 101 trial results: mPFS (13.8 mos. vs 7.2 mos.); ORR (51.4% vs 25.7%); 39% reduction in risk of disease progression; received anticancer drug therapies (20.8% vs […]Read More